Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M309,970Revenue (TTM) $M70,182Net Margin (%)21.9Altman Z-Score5.3
Enterprise Value $M293,464EPS (TTM) $5.5Operating Margin %25.9Piotroski F-Score6
P/E(ttm)20.5Beneish M-Score-2.6Pre-tax Margin (%)27.0Higher ROA y-yY
Price/Book4.310-y EBITDA Growth Rate %4.0Quick Ratio2.5Cash flow > EarningsY
Price/Sales4.55-y EBITDA Growth Rate %5.9Current Ratio2.8Lower Leverage y-yN
Price/Free Cash Flow21.6y-y EBITDA Growth Rate %-10.1ROA % (ttm)11.6Higher Current Ratio y-yY
Dividend Yield %2.7PEG3.5ROE % (ttm)21.7Less Shares Outstanding y-yY
Payout Ratio %55.0Shares Outstanding M2,751ROIC % (ttm)26.9Gross Margin Increase y-yN

Gurus Latest Trades with JNJ

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
JNJTweedy Browne 2016-03-31 Reduce-0.93%$95.75 - $109.14
($103.39)
$ 112.168%Reduce -8.39%3,383,445
JNJFirst Eagle Investment 2016-03-31 Reduce-0.49%$95.75 - $109.14
($103.39)
$ 112.168%Reduce -62.31%1,142,872
JNJYacktman Focused Fund 2016-03-31 Reduce-0.45%$95.75 - $109.14
($103.39)
$ 112.168%Reduce -8.00%2,300,000
JNJT Rowe Price Equity Income Fund 2016-03-31 Reduce-0.33%$95.75 - $109.14
($103.39)
$ 112.168%Reduce -15.23%3,961,300
JNJRobert Olstein 2016-03-31 Reduce-0.28%$95.75 - $109.14
($103.39)
$ 112.168%Reduce -29.58%50,000
JNJJoel Greenblatt 2016-03-31 Add0.24%$95.75 - $109.14
($103.39)
$ 112.168%Add 511.44%242,043
JNJDonald Yacktman 2016-03-31 Reduce-0.18%$95.75 - $109.14
($103.39)
$ 112.168%Reduce -3.22%7,080,500
JNJJohn Rogers 2016-03-31 Add0.03%$95.75 - $109.14
($103.39)
$ 112.168%Add 2.31%850,915
JNJRuane Cunniff 2016-03-31 Reduce-0.03%$95.75 - $109.14
($103.39)
$ 112.168%Reduce -78.50%13,925
JNJTom Gayner 2016-03-31 Add0.02%$95.75 - $109.14
($103.39)
$ 112.168%Add 0.93%610,800
JNJKen Fisher 2016-03-31 Add0.01%$95.75 - $109.14
($103.39)
$ 112.168%Add 0.35%10,854,263
JNJRichard Pzena 2016-03-31 Add0.01%$95.75 - $109.14
($103.39)
$ 112.168%Add 0.92%1,185,329
JNJCharles Brandes 2016-03-31 Reduce-0.01%$95.75 - $109.14
($103.39)
$ 112.168%Reduce -3.20%146,253
JNJMario Gabelli 2016-03-31 Add$95.75 - $109.14
($103.39)
$ 112.168%Add 1.60%337,588
JNJBarrow, Hanley, Mewhinney & Strauss 2016-03-31 Reduce$95.75 - $109.14
($103.39)
$ 112.168%Reduce -0.10%15,327,465
JNJDodge & Cox 2016-03-31 Reduce$95.75 - $109.14
($103.39)
$ 112.168%Reduce -1.77%34,808
JNJTweedy Browne 2015-12-31 Reduce-0.45%$93.42 - $105.25
($100.75)
$ 112.1611%Reduce -4.22%3,693,349
JNJFirst Eagle Investment 2015-12-31 Add0.37%$93.42 - $105.25
($100.75)
$ 112.1611%Add 91.19%3,032,177
JNJYacktman Focused Fund 2015-12-31 Reduce-0.17%$93.42 - $105.25
($100.68)
$ 112.1611%Reduce -3.85%2,500,000
JNJDonald Yacktman 2015-12-31 Reduce-0.15%$93.42 - $105.25
($100.75)
$ 112.1611%Reduce -3.23%7,316,129
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

JNJ is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


JNJ: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Kapusta Ronald AController, CAO 2016-05-10Sell3,957$114.77-1.81view
Stoffels PaulusChief Scientific Officer 2016-02-17Sell125,000$102.4310.02view
Fasolo PeterVP, Global Human Resources 2016-02-03Sell151,385$104.128.23view
Ullmann Michael HVP, General Counsel 2015-11-20Sell17,650$102.479.97view
Caruso Dominic JVP, Finance; CFO 2015-11-02Sell20,569$102.2110.25view
Kapusta Ronald AController, CAO 2015-10-23Sell6,239$99.6813.05view
PRINCE CHARLESDirector 2015-08-06Buy2,500$99.2513.54view
PRINCE CHARLESDirector 2015-06-02Buy2,500$99.2213.58view
Stoffels PaulusChief Scientific Officer 2015-04-28Sell187,250$100.7311.87view
Fasolo PeterVP, Global Human Resources 2015-03-05Sell115,307$102.410.05view

Press Releases about JNJ :

Quarterly/Annual Reports about JNJ:

    News about JNJ:

    Articles On GuruFocus.com
    'Party Drug' Could Be Johnson & Johnson's Entry Into Antidepressant Market May 22 2016 
    U.S. Stocks Trade Flat at Start of Week May 09 2016 
    Johnson & Johnson a Legendary Dividend Stock May 08 2016 
    UnitedHealth’s Obamacare Changes to Affect Healthcare Sector Apr 27 2016 
    Johnson & Johnson Beats 1st-Quarter Expectations, Improves Guidance Apr 27 2016 
    How to Know When You Can Retire With Dividend Investing Apr 13 2016 
    Periodic Payments vs. Lump Sum: When's the Right Time to Pull the Plug? Apr 07 2016 
    Dividend and Value Opportunities in the Large-Cap Pharmaceutical Space Apr 05 2016 
    Is Zimmer Biomet Worth the Risk? Apr 01 2016 
    A Cheap Dividend Aristocrat Yielding Over 4% Mar 02 2016 

    More From Other Websites
    California sues Johnson & Johnson over marketing for pelvic mesh May 24 2016
    California AG sues Johnson & Johnson over marketing for pelvic mesh May 24 2016
    Trump says decision to seek donations followed GOP request May 24 2016
    U.S. FDA Expands Indication of INVOKAMET® (canagliflozin/metformin HCl) to Include First-Line... May 24 2016
    Tuesday links: consistent declines May 24 2016
    The Top 5 Johnson & Johnson Shareholders (JNJ) May 24 2016
    4 Dow Members Bucking the Negative Trend May 24 2016
    6:38 am Johnson & Johnson presents Phase 3 data showing that a significantly greater proportion of... May 24 2016
    Samsung Bioepis applies for approval to sell Remicade biosimilar in U.S. May 23 2016
    What Hedge Funds Think About Achillion Pharmaceuticals, Inc. (ACHN)? May 23 2016
    France faults Bial and Biotrial over fatal drug trial May 23 2016
    Boomer Esiason Foundation Announces Collaboration with Johnson & Johnson for First-of-Its-Kind TRU... May 23 2016
    Warren Buffett’s Favorite Consumer Products Stocks May 23 2016
    Stocks for rainy day trades May 20 2016
    Wal-Mart PT Hiked; J&J Started At Sell; ICE Is A Buy May 20 2016
    One Reason Why Johnson & Johnson (JNJ) Stock Is Retreating Today May 20 2016
    J&J is Worth as Much as Gilead, Biogen, Mylan, Celgene and Teva Combined. It's Time to Sell. May 20 2016
    Johnson & Johnson Stock Trades Ex-Dividend Friday (JNJ) May 20 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)